Question 1

What is cardiomyopathy, familial hypertrophic 27?

Accepted Answer

Familial hypertrophic cardiomyopathy 27 is a heart condition that primarily affects the structure and function of the heart. It is associated with pathogenic variants in the ALPK3 gene, which plays an important role in cardiac muscle regulation. Individuals with this condition may present in infancy or early childhood, although the exact age at onset can vary. Precise prevalence estimates are not well established, and symptoms can range from mild to severe.

Question 2

What are the symptoms of cardiomyopathy, familial hypertrophic 27?

Accepted Answer

The clinical presentation is dominated by cardiac abnormalities. Characteristic features include endocardial fibroelastosis, pterygium, and a prolonged QT interval, which are reported to be always present. Many affected individuals also experience structural and functional abnormalities such as cardiomegaly, hypertrophic cardiomyopathy (both concentric and ventricular septal hypertrophy), and impaired myocardial contractility. Less frequent findings include nonimmune hydrops fetalis, tricuspid regurgitation, mitral regurgitation, right ventricular hypertrophy, cardiac arrest, left ventricular diastolic dysfunction, congestive heart failure, ventriculomegaly, and cardiomyocyte hypertrophy. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes cardiomyopathy, familial hypertrophic 27?

Accepted Answer

This condition is caused by pathogenic variants in the ALPK3 gene. The ALPK3 protein is believed to be important for the proper development and function of cardiac muscle, and disruptions can lead to the characteristic structural and electrical abnormalities in the heart. Familial hypertrophic cardiomyopathy 27 follows an autosomal recessive inheritance pattern, meaning that affected individuals inherit two copies of the pathogenic variant, one from each parent. Families are encouraged to seek genetic counseling to further understand the implications for relatives and options for future family planning. Associated genes include ALPK3.

Question 4

How is cardiomyopathy, familial hypertrophic 27 inherited?

Accepted Answer

cardiomyopathy, familial hypertrophic 27 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is cardiomyopathy, familial hypertrophic 27 diagnosed?

Accepted Answer

Definitive diagnosis of familial hypertrophic cardiomyopathy 27 is achieved through molecular genetic testing that identifies pathogenic variants in the ALPK3 gene. Clinical evaluation, including detailed cardiac imaging and electrocardiograms, helps in assessing the structural and electrical features of the heart. Because many of the cardiac features overlap with other conditions, genetic testing is essential to confirm the diagnosis and differentiate it from similar disorders.

Question 6

Are there treatments for cardiomyopathy, familial hypertrophic 27?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as no treatments are specifically approved for familial hypertrophic cardiomyopathy 27. A tailored approach typically involves a multidisciplinary team, including cardiologists and genetic counselors, to manage the various cardiac manifestations. In addition to treating active symptoms, regular surveillance is an essential part of long-term care, helping to identify potential complications before they become serious. Patients and families should discuss treatment options with their healthcare team to determine which therapies and monitoring strategies may be appropriate for their specific situation.

Question 7

Are there clinical trials for cardiomyopathy, familial hypertrophic 27?

Accepted Answer

Yes, there is currently 1 active clinical trial for cardiomyopathy, familial hypertrophic 27 registered on ClinicalTrials.gov. Clinical trials test new treatments, procedures, or approaches. Your healthcare provider can help determine if a trial might be appropriate for your situation. Visit the Treatment section of this page for more details.

Question 8

What complications can arise from cardiomyopathy, familial hypertrophic 27?

Accepted Answer

Complications from cardiomyopathy, familial hypertrophic 27 can include serious heart issues like congestive heart failure, cardiac arrest, and impaired heart function. Some individuals may also experience arrhythmias, which are irregular heartbeats that can be dangerous. Regular monitoring and care are important to manage these risks and catch any complications early.

Question 9

How does cardiomyopathy, familial hypertrophic 27 affect daily life?

Accepted Answer

Living with cardiomyopathy, familial hypertrophic 27 can mean making some adjustments in daily life. Individuals may need to monitor their symptoms closely and avoid strenuous activities that could put extra strain on the heart. Support from healthcare providers and family can help manage symptoms and improve quality of life.

Question 10

What is the prognosis for someone with cardiomyopathy, familial hypertrophic 27?

Accepted Answer

The prognosis for cardiomyopathy, familial hypertrophic 27 varies widely among individuals. Some may have a stable condition with manageable symptoms, while others may face more severe complications. With good medical care and regular monitoring, many people can improve their quality of life and manage their symptoms effectively.

Question 11

What should families consider for future family planning with cardiomyopathy, familial hypertrophic 27?

Accepted Answer

Families considering future children should think about the genetic aspects of cardiomyopathy, familial hypertrophic 27. Since this condition follows an autosomal recessive inheritance pattern, genetic counseling can help families understand the risks of passing the condition to their children. This guidance can be very helpful in making informed family planning decisions.

Research Type	Count	% of Total
Testing and diagnosis research	5	28%

Kisho

cardiomyopathy, familial hypertrophic 27

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

cardiomyopathy, familial hypertrophic 27

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is cardiomyopathy, familial hypertrophic 27?

What are the symptoms of cardiomyopathy, familial hypertrophic 27?

What causes cardiomyopathy, familial hypertrophic 27?

How is cardiomyopathy, familial hypertrophic 27 inherited?

How is cardiomyopathy, familial hypertrophic 27 diagnosed?

Are there treatments for cardiomyopathy, familial hypertrophic 27?

Are there clinical trials for cardiomyopathy, familial hypertrophic 27?

What complications can arise from cardiomyopathy, familial hypertrophic 27?

How does cardiomyopathy, familial hypertrophic 27 affect daily life?

What is the prognosis for someone with cardiomyopathy, familial hypertrophic 27?

What should families consider for future family planning with cardiomyopathy, familial hypertrophic 27?

Explore clinical features

Recent Publications